Oxford, UK, – ProImmune Ltd., a leader in services for understanding immune responses, has launched the B cell ELISpot assay as a service. The B cell ELISpot assay is central to the characterization of adaptive immune responses to infection, immune modulators, vaccines and therapeutic agents.

Used to quantify the number of memory B cells that can be re-stimulated to produce antibody against a specific antigen, B cell ELISpot enables the activity of antibody-secreting memory B cells to be characterized at a cellular level. This gives a more detailed reading of immune responses in contrast to an ELISA-type assay, which measures total levels of secreted antibodies in a sample.

Dr Nikolai Schwabe, CEO of ProImmune said: “The B cell ELISpot is a highly valuable assay offering a superior method for characterisation of memory antibody responses, the investigation of which forms a mainstay of evaluating functional immune responses. Although the assay is technically challenging, requiring extensive experience, when performed correctly it is very robust and is therefore very well suited to be run as a core facility service.”

To read further information about the B Cell ELISpot Assay Service, please visit https://bit.ly/HPHW4R

ProImmune is a private biotechnology company that specializes in providing products and services for antigen characterization, immune monitoring and the design of biological drugs with reduced immunogenicity risk. ProImmune has a wide range of customers, including leading pharmaceutical and biotechnology companies, as well as clinical and academic research institutes throughout the world.